Agriculture business drives successful start to year: Bayer
The CEO reiterated earlier guidance for 2022 core earnings per share to reach about 7.00 euros, up from 6.51 euros last year, excluding the effect of currency swings.
Frankfurt: German diversified group Bayer has seen a "very successful start to the year", driven by favourable agricultural markets, it said on Monday.
"In the agriculture business, in particular, we see a much more positive market environment than in previous years," Chief Executive Werner Baumann said in a written speech posted on the company's website on Monday.
The speech will be delivered at the annual shareholder meeting scheduled for Friday.
The maker of pharmaceuticals, seeds and pesticides added the economic consequences of the war in Ukraine and sanctions imposed on Russia were not yet visible in the first quarter.
The CEO reiterated earlier guidance for 2022 core earnings per share to reach about 7.00 euros ($7.50), up from 6.51 euros last year, excluding the effect of currency swings.
Read also: Bayer launches campaign 'Preserve The Uterus' to stall untimely hysterectomies in India
Baumann added that despite global uncertainties he was confident of a very successful year.
Bayer is due to release detailed first-quarter figures on May 10.
Read also: Bayer appoints Tara Frenkl as new head of oncology development at oncology strategic business unit
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.